Clinical Trials Logo

Filter by:
NCT ID: NCT02024646 Completed - Psoriatic Arthritis Clinical Trials

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

AMVISION-2
Start date: March 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

NCT ID: NCT02022553 Completed - Clinical trials for Rectal Cancer T3-4N0-2M0

Procedure RACHEL in Complex Treatment of Rectal Cancer

RACHEL
Start date: February 2006
Phase: N/A
Study type: Interventional

AIM OF RESEARCH. The aim of our research is to improve the results of the combined treatment of patients with locally advanced rectal cancer using endovascular methods and reservoir and plastic surgery. TASKS OF RESEARCH. 1. To assess the immediate and long-term results of combined (chemoradiation and surgical) treatment for locally advanced rectal cancer. 2. To make a comparative evaluation of the results of independent surgical and combined (chemoradiation and surgery) treatment of patients with locally advanced rectal cancer. 3. To examine functional results of surgical treatment with the formation of "neosphincter" and "neorectum" in patients with colorectal cancer.. 4. To study features of blood supply to the rectum from the pools of the inferior mesenteric and internal iliac arteries, using the method of selective angiography, in connection with the development of endovascular treatment of rectal cancer. 5. To develop and introduce into clinical practice method of one-stage selective intra-arterial oil chemoembolization of upper, middle and lower rectal arteries in patients with locally advanced rectal cancer, who have a contraindication to preoperative radiotherapy. 6. To assess the immediate and long-term results of combined (endovascular and surgical) treatment for locally advanced rectal cancer. 7. To optimize tactics of combined treatment of locally advanced rectal cancer by developing an algorithm of using chemoradiotherapy and endovascular interventions in the preoperative period. NOVELTY OF RESEARCH. 1. As a result of research will be designed and implemented a new method of selective intra-arterial chemoembolization in rectal arteries preoperatively in patients with locally advanced rectal cancer. 2. Substantiated high effectiveness of the proposed technique for the removal of colonic obstruction and, as a consequence perform radical surgical treatment of these patients. 3. First developed dosage and concentration of chemotherapeutic agent and embolic agent for safe injection when performing selective intra-arterial chemoembolization of rectal arteries. 4. Developed complex techniques of selective intra-arterial chemoembolization of rectal arteries preoperatively in patients with locally advanced rectal cancer. 5. Will be made a comparative analysis of the postoperative period and the evaluation of the quality of life of operated patients Obtained data will be presented for use in clinical practice. POSSIBLE APPLICATION AREAS. Results of the research designed for use in the treatment process of departments of Coloproctology, oncology, as well as the educational process of higher and secondary medical institutions. EXPECTED EFFECTIVENESS. It is expected that the use of this method of treatment of patients with locally advanced rectal cancer in clinical practice will provide pronounced effect: 1. Medical and social - improving the quality of care, preservation of social activity of patients, reducing mortality; 2. Economic - reducing the time of patients' treatment and reducing the number of therapeutic manipulation; 3. Science and Technology - improving of the training level of medicine workers in the treatment of patients with rectal cancer.

NCT ID: NCT02021318 Completed - Clinical trials for Anemia in Chronic Kidney Disease in Non-dialysis Patients

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa

Dolomites
Start date: March 12, 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.

NCT ID: NCT02021292 Completed - Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

MERIT-1
Start date: August 20, 2014
Phase: Phase 2
Study type: Interventional

Study to evaluate if macitentan is efficient, safe and tolerable enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH).

NCT ID: NCT02020967 Completed - Acromegaly Clinical Trials

Programme of Acromegaly Screening in Patients With Associated Somatic Disorders

ACROSCREEN
Start date: December 5, 2013
Phase:
Study type: Observational

The primary objective of the protocol is to define percentage of patients with acromegaly in relation to the total number of screened patients with confirmed clinically significant set of associated somatic disorders with the help of laboratory (Insulin-like Growth Factor I, Growth Hormone, Oral Glucose-Tolerance Test [IGF-1, GH, OGTT]) and instrumental examination methods (Magnetic Resonance Imaging [MRI]).

NCT ID: NCT02020369 Completed - Clinical trials for Hemophilia A With Inhibitors

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX

Start date: April 2014
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX

NCT ID: NCT02019472 Completed - Clinical trials for Arthritis, Rheumatoid

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

SIRROUND-H
Start date: April 4, 2014
Phase: Phase 3
Study type: Interventional

The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate responders to methotrexate.

NCT ID: NCT02016261 Completed - Clinical trials for Recurrent Depressive Disorder

Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine

Start date: December 2013
Phase: Phase 4
Study type: Interventional

Open label, non-comparative, prospective study to evaluate cognitive functioning in remitted depression outpatients during long-term preventive treatment with Fluvoxamine (Fevarin®)

NCT ID: NCT02010931 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients

Start date: September 2013
Phase:
Study type: Observational

A retrospective analysis of historical data looking at relapse free survival and overall survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia patients.

NCT ID: NCT02009865 Completed - Clinical trials for Hypertriglyceridemia

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

EVOLVEII
Start date: December 16, 2013
Phase: Phase 3
Study type: Interventional

This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia. The study consists of an approximately 8-week screening period that includes a diet and lifestyle stabilization and washout period and a 12-week treatment period.